Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484874 | 1.00 | LMNA (0.36) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL3317300 | 0.89 | KCNH2 (0.37) | — | |
| SCHEMBL3316366 | 0.89 | KCNH2 (0.37) | — | |
| SCHEMBL3316369 | 0.89 | KCNH2 (0.37) | — | |
| SCHEMBL3816722 | 0.88 | HRH3 (0.40) | HRH3ALDH1A1L3MBTL1HTR4ADRB3 | |
| SCHEMBL21725300 | 0.84 | LMNA (0.33) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL24713145 | 0.83 | LMNA (0.34) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL13755999 | 0.83 | — | — | |
| SCHEMBL17788463 | 0.82 | HRH3 (0.34) | LMNASMN1; SMN2HTTHRH3MAPT | |
| SCHEMBL19098600 | 0.81 | HRH3 (0.35) | HRH3CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3336084-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-9944626-B2 | 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9708296-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | WUXI APPTEC (HONG KONG) CO., LIMITED (HK) | 2017-07-06 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| EP-1913004-B1 | 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS INC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7576092-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | LMNA 4258/4885SMN1; SMN2 4366/4885HTT 3004/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | LMNA 1292/4885SMN1; SMN2 1519/4885HTT 4782/4885 |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | LMNA 2604/4885SMN1; SMN2 3640/4885HTT 920/4885 |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | LMNA 4393/4885SMN1; SMN2 4269/4885HTT 3702/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | LMNA 4258/4885SMN1; SMN2 4366/4885HTT 3004/4885 |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | HRH4, HRH1, HRH2 | LMNA 4871/4885SMN1; SMN2 4621/4885HTT 419/4885 |
| US-20170190713-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | LMNA 4393/4885SMN1; SMN2 4269/4885HTT 3702/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | LMNA 3978/4885SMN1; SMN2 524/4885HTT 19/4885 |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | LMNA 2604/4885SMN1; SMN2 3640/4885HTT 920/4885 |
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | HIF1AN, EGLN3, EGLN2 | LMNA 2604/4885SMN1; SMN2 3640/4885HTT 920/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | LMNA 4710/4885SMN1; SMN2 2954/4885HTT 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.